Efficacy of wIRA in the treatment of sacroiliitis in male patients with ankylosing spondylitis and its effect on serum VEGF levels

Table 1 Baseline information of the patients

	Group A	Group B	t/x²-statistic	P value
Age (years)	32.05 ± 10.96	32.60 ± 13.01	− 0.145	0.886
Disease course (years)	6.92 ± 3.21	6.40 ± 2.70	0.554	0.583
HLA-27 positive rates	95% (57/60)	100% (60/60)	1.026	0.311
CRP (mg/L)	30.21 ± 6.98	30.04 ± 8.33	0.070	0.945
VEGF (pg/ml)	180.22 ± 18.51	182.87 ± 23.31	− 0.399	0.692
BASDAI scores (0–10)	8.30 ± 0.78	8.43 ± 0.80	− 0.522	0.604
Pain VAS scores (0–10)	8.90 ± 0.52	8.80 ± 0.54	0.597	0.554
Morning stiffness-VAS scores (0–10)	8.79 ± 0.55	8.77 ± 0.53	0.145	0.885
RI	0.52 ± 0.04	0.54 ± 0.06	− 1.17	0.249

HLA-27 human leukocyte antigen B27, CRP C-reactive protein, VEGF vascular endothelial growth factor, BASDAI bath ankylosing spondylitis disease activity index, RI resistance index, VAS visual analogue scale

ISSN: 1749-799X